FDA grants emergency use authorisation for ID NOW COVID-19 EUA Test for coronavirus.- Abbott

Abbott announced that the FDA has issued Emergency Use Authorization (EUA) for ID NOW COVID-19 EUA Test, a molecular point-of-care test for the detection of novel coronavirus (COVID-19), delivering positive results in as little as five minutes and negative results in 13 minutes. The test will run on the company's ID NOW platform, providing rapid results in a wide range of healthcare settings such as physicians' offices, urgent care clinics and hospital emergency departments.Comment: Abbott will be making ID NOW COVID-19 tests available next week (April 2020) to healthcare providers in urgent care settings in the U.S., where the majority of ID NOW instruments are in use. the Abbott ID NOW COVID-19 test comes a week after the company launched its Abbott m2000 RealTime SARS-CoV-2 EUA test, which runs on the m2000 RealTime System located in hospital and reference labs around the world.